CStone Pharmaceuticals

Research CStone Pharmaceuticals (2616.HK) on Bullrun: market cap HKD 7.92B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker2616.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 7.92B
Financial periodFY2025
RevenueCNY 269.58M
Revenue growth-33.8%
Net income-CNY 437.00M
Free cash flow-CNY 327.75M
Gross margin19.0%

Valuation Snapshot

latest market cap is HKD 7.92B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 269.58M	-CNY 437.00M	-CNY 327.75M	19.0%	-0.31	CNY 753.70M	CNY 348.52M	CNY 616.77M
FY2024	CNY 407.21M	-CNY 91.21M	-CNY 303.21M	59.0%	-0.07	CNY 387.94M	CNY 355.97M	CNY 363.87M
FY2023	CNY 463.84M	-CNY 367.23M	-CNY 653.89M	65.6%	-0.29	CNY 996.67M	CNY 363.45M	CNY 456.83M
FY2022	CNY 481.36M	-CNY 902.68M	-CNY 712.56M	57.8%	-0.77	CNY 558.68M	CNY 286.29M	CNY 449.33M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 7.92B	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is CStone Pharmaceuticals's market cap?

CStone Pharmaceuticals's market capitalization is HKD 7.92B.

What does CStone Pharmaceuticals do?

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.